newsfilter
← Latest News
Business Wire·

Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Research Will Use Lunit’s AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology Summit Therapeutics Inc. (NASDAQ:SMMT) and Lunit Inc.